Stock Watch: Pfizer Gets Back To Business As Usual
New Launches Come Into Focus As COVID-19 Vaccine Sales Recede
Executive Summary
Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.